Experience with the carbamylated monomeric allergoid Lais® for sublingual immunotherapy in patients with grass pollen or mite-induced allergic rhinoconjunctivitis

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


The article presents the results of a prospective noncomparative study of carbamylated monomeric allergoid Lais ® for sublingual immunotherapy (SLIT) in patients with allergic rhinoconjunctivitis caused by pollen grasses. We suggest that SLIT using Lais ® sublingual tablets is an effective and well-tolerated method of treatment.

Full Text

Restricted Access

About the authors

I V Danilycheva

Institute of Immunology

Email: ivdanilycheva@mail.ru

N I Ilina

Institute of Immunology

A E Shulzhenko

Institute of Immunology


  1. Lombardi C., Gargioni S., Melchiorre A. et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: Multicenter post-marketing surveillance study. J. Allergy. 2001, v. 56, p. 989-992.
  2. Quercia O., Bruno M.E., Compalati E. et al. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens. J. Eur. Ann. Allergy Clin. Immunol. 2011, v. 43, p. 176-183.
  3. Mösges R., Ritter B., Kayoko G. et al. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets. J. Acta Dermatoven. APA. 2010, v. 19, p. 3-10.
  4. Гущин И.С., Курбачева О.М. Аллергия и аллергенспецифическая иммунотерапия. М., «Фармарус Принт Медиа». 2010, 228 с.
  5. Passalacqua G., Albano M., Fregonese L. et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. J. Lancet. 1998, v. 351, p. 629-632.
  6. Rossi R.E., Monasterolo G. Safety of ultra-rush (two hours) sublingual swallow immunotherapy in allergic patients. J. Giorn. it allergol. immunol. clin. 2002, v. 12, p. 221-226.
  7. Agostinis F., Foglia C., Bruno M.E., Falagiani P. Efficacy, safety and tolerability of sublingual monomeric allergoid in tablets given without up-dosing to pediatric patients with allergic rhinitis and/or asthma due to grass pollen. Eur. Ann. Allergy Clin. Immunol. 2009, v. 41, p. 177-180.
  8. Passali D., Mosges R., Passali G.C. et al. Safety, tolerability, and efficacy of sublingual allergoid immunotherapy with three different shortened up-dosing administration schedules. J. Acta Otorhinolaryngologica Italica. 2010, v. 30, p. 131-137.
  9. Giordano T., Quarta C., Bruno M.E. et al. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase. J. Eur. Ann. Allergy Clin. Immunol. 2006, v. 38, p. 310-312.
  10. Agostinis F., Tellarini L., Canonica G.W. et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. J. Allergy. 2005, v. 60, p. 133.

Copyright © Pharmarus Print Media, 2015

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies